T-DXd Reevaluated in HER2-Low/HER2-Negative Breast Cancer After New Trials

HER2-ultralow Metastatic Breast Cancer Companion Diagnostic Approved by FDA

Summary Roche’s PATHWAY anti-HER2/neu (4B5) test has received FDA approval to identify patients with HR-positive, HER2-ultralow metastatic breast cancer for potential treatment with ENHERTU. Key Takeaways New HER2 Category: The test can now detect “HER2-ultralow” status, a recently defined category for patients with minimal HER2 expression. Expanded Treatment Options: HER2-ultralow patients may now be eligible for treatment with ENHERTU, offeri…

T-DXd Reevaluated in HER2-Low/HER2-Negative Breast Cancer After New Trials

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast cancer and the need for HER2-negative data with T-DXd.